Investigator-Sponsored Phase 2 Study Results Show pSivida’s Medidur® Fully Controlled Uveitis for Two Years with No Recurrence of Disease While Visual Acuity Continued to Improve

ByConnor Hodde

WATERTOWN, Mass., July 14, 2016 (GLOBE NEWSWIRE) — pSivida Corp. (NASDAQ:PSDV) (ASX:PVA), a leader in the development of sustained release drug delivery products primarily for eye diseases, announced that the results from an investigator-sponsored Phase 2 study of pSivida’s Medidur showed no recurrence of uveitis in 11 eyes treated with Medidur during the two years following implantation, while six of 10 fellow eyes without Medidur experienced recurrence. Furthermore, although visual acuity typically declines over time in uveitis patients, all Medidur-treated eyes had a significant improvement in mean visual acuity compared to baseline throughout the two years, and mean visual acuity showed successive improvement at two years over one year.

Read the entire article here.

Similar Posts

SDM Photocoagulation Superior to Intravitreal Injections of BCZ in the Treatment of CSC

ByConnor Hodde

A recent study was conducted to evaluate the treatment of central serous chorioretinopathy (CSC) with either subthreshold diode laser MicroPulse (SDM) or intravitreal bevacizumab (BCZ). The study was conducted over a period of 10 months and examined 52 eyes of 52 patients with (a) treatment with SDM at the active leakage site guided by fluorescein…

Partnership Aims to Take Advantage of Preclinical Ophthalmology Developments

ByConnor Hodde

Rafal Farjo, PhD, COO of eyecro, told Outsourcing-pharma.com that the “demand for ophthalmology studies is increasing.  Many research scientists are uncovering new mechanisms and targets for ophthalmic disease, it is also becoming apparent that there is pathology in common with many other clinical indications.   eyecro specializes in ophthalmic studies of preclinical efficacy, pharmacokinetics, toxicology, and…

eyecro co-authors paper in Molecular and Cellular Biology studying mechanisms leading to Diabetic Retinopathy

ByConnor Hodde

Serum retinol-binding protein (RBP4) is the sole specific transport protein for retinol in the blood, but it is also an adipokine with retinol-independent, pro-inflammatory activity associated with obesity, insulin resistance, type 2 diabetes, and cardiovascular disease.  Here we show that RBP4-Tg mice develop progressive retinal degeneration, characterized by photoreceptor ribbon synapse deficiency and subsequent bipolar…

New Trial Shows Drugs are Effective for Diabetic Macular Edema

ByConnor Hodde

 Diabetes is a significant risk factor for developing eye diseases. The most common diabetic eye disease and a leading cause of blindness is diabetic retinopathy.  Americans with diabetic retinopathy have diabetic macular edema (DME) in which fluid leaks into the macula, the area of the retina used when looking straight ahead.  Over the past few…

Solving Three Major Age-related Eye Conditions in One Go

ByConnor Hodde

Vascular endothelial growth factor A (VEGF-A) is looking like more of an optical troublemaker than ever before – as well as its link with wet age-related macular degeneration (AMD), it also might be causing dry AMD and even age-related cataracts.  Therefore, Massachusetts General Hospital researcher and paper author, Dr Alexander Marneros, is looking at what processes…

EyeCRO scientist contributes to a paper published in Experimental Eye Research

ByConnor Hodde

EyeCRO scientist Jarrod Harman contributed to a paper focused on X-linked juvenile retinoschisis published in Experimental Eye Research. This paper expands the mechanistic understanding of XLRS. Read the full paper here https://www.sciencedirect.com/science/article/pii/S0014483523002129?dgcid=coauthor